艾滋病相关隐球菌性脑膜炎中两性霉素B药敏的体外-临床相关性
In vitro-clinical correlations for amphotericin B susceptibility in AIDS-associated cryptococcal meningitis.
作者信息
Larsen R A, Bauer M, Brouwer A E, Sanchez A, Thomas A M, Rajanuwong A, Chierakul W, Peacock S J, Day N, White N J, Rinaldi M G, Harrison T S
机构信息
Department of Medicine (Infectious Diseases), 2020 Zonal Ave., IRD Room 620, MC 9520, University of Southern California, Los Angeles, CA 90033, USA.
出版信息
Antimicrob Agents Chemother. 2007 Jan;51(1):343-5. doi: 10.1128/AAC.00742-06. Epub 2006 Oct 23.
Abstract
Reliable measures of antifungal drug susceptibility are needed. We tested the susceptibility of Cryptococcus neoformans from patients treated with amphotericin B. In vitro susceptibility employed a modified broth macrodilution method. We demonstrate a strong correlation between the quantitative measures of in vitro amphotericin B susceptibility and the quantitative response observed in patients.
摘要
需要可靠的抗真菌药物敏感性测量方法。我们测试了接受两性霉素B治疗患者的新型隐球菌的敏感性。体外敏感性采用改良肉汤稀释法。我们证明了体外两性霉素B敏感性的定量测量与患者中观察到的定量反应之间存在强相关性。
相似文献
1
In vitro-clinical correlations for amphotericin B susceptibility in AIDS-associated cryptococcal meningitis.艾滋病相关隐球菌性脑膜炎中两性霉素B药敏的体外-临床相关性
Antimicrob Agents Chemother. 2007 Jan;51(1):343-5. doi: 10.1128/AAC.00742-06. Epub 2006 Oct 23.
2
Correlation of susceptibility of Cryptococcus neoformans to amphotericin B with clinical outcome.新型隐球菌对两性霉素 B 的敏感性与临床结果的相关性。
Antimicrob Agents Chemother. 2011 Dec;55(12):5624-30. doi: 10.1128/AAC.00034-11. Epub 2011 Sep 26.
3
Cryptococcal meningitis in AIDS.艾滋病相关性隐球菌性脑膜炎
Indian J Med Sci. 2002 Dec;56(12):593-7.
4
Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS.从艾滋病患者分离出的新型隐球菌的时间-杀菌曲线。
Med Mycol. 2000 Jun;38(3):201-7. doi: 10.1080/mmy.38.3.201.207.
5
Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole.复发性新型隐球菌性脑膜炎患者的系列新型隐球菌分离株对两性霉素B和氟康唑的敏感性
Antimicrob Agents Chemother. 1993 Jun;37(6):1383-6. doi: 10.1128/AAC.37.6.1383.
6
7
Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis.脂质体两性霉素B短疗程诱导治疗隐球菌性脑膜炎的实验模型
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00090-17. Print 2017 Jun.
8
Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease.艾滋病相关隐球菌病氟康唑维持治疗期间唑类耐药性的产生
AIDS. 2001 Nov 23;15(17):2344-5. doi: 10.1097/00002030-200111230-00026.
9
Meningitis due to Cryptococcus neoformans: treatment with posaconazole.新型隐球菌性脑膜炎：泊沙康唑治疗
Curr HIV Res. 2012 Oct;10(7):620-3. doi: 10.2174/157016212803305970.
10
Antifungal susceptibility and multilocus sequence typing (MLST) of Cryptococcus neoformans complex from HIV-associated cryptococcal meningitis patients in Manaus, Amazonas, Brazil.巴西亚马孙州玛瑙斯市HIV相关隐球菌性脑膜炎患者中新隐球菌复合体的抗真菌药敏性及多位点序列分型
Braz J Microbiol. 2024 Sep;55(3):2603-2611. doi: 10.1007/s42770-024-01378-y. Epub 2024 May 16.
引用本文的文献
1
Antifungal Resistance in Cryptococcal Infections.隐球菌感染中的抗真菌耐药性
Pathogens. 2024 Jan 29;13(2):128. doi: 10.3390/pathogens13020128.
2
Physiological Differences in Cryptococcus neoformans Strains versus and Their Effects on Antifungal Susceptibility.新型隐球菌菌株的生理差异及其对抗真菌药敏性的影响
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02108-16. Print 2017 Mar.
3
Correlation of anti-fungal susceptibility with clinical outcomes in patients with cryptococcal meningitis.隐球菌性脑膜炎患者抗真菌药敏与临床结局的相关性。
BMC Infect Dis. 2012 Dec 20;12:361. doi: 10.1186/1471-2334-12-361.
4
Cryptococcus neoformans: the model organism for yeast antifungal drug susceptibility testing.新型隐球菌：酵母抗真菌药敏试验的模式生物。
Mycopathologia. 2012 Jun;173(5-6):435-43. doi: 10.1007/s11046-012-9524-0. Epub 2012 Feb 10.
5
Correlation of susceptibility of Cryptococcus neoformans to amphotericin B with clinical outcome.新型隐球菌对两性霉素 B 的敏感性与临床结果的相关性。
Antimicrob Agents Chemother. 2011 Dec;55(12):5624-30. doi: 10.1128/AAC.00034-11. Epub 2011 Sep 26.
6
Major role for amphotericin B-flucytosine combination in severe cryptococcosis.两性霉素B-氟胞嘧啶联合用药在重症隐球菌病中起主要作用。
PLoS One. 2008 Aug 6;3(8):e2870. doi: 10.1371/journal.pone.0002870.
本文引用的文献
1
Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.采用各种抗真菌药敏试验方法所获得的结果并不能预测隐球菌病患者的早期临床结局。
Antimicrob Agents Chemother. 2006 Jul;50(7):2464-70. doi: 10.1128/AAC.01520-05.
2
Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans.新型隐球菌体外和体内氟康唑剂量反应曲线的相关性
Antimicrob Agents Chemother. 2005 Aug;49(8):3297-301. doi: 10.1128/AAC.49.8.3297-3301.2005.
3
Baseline correlation and comparative kinetics of cerebrospinal fluid colony-forming unit counts and antigen titers in cryptococcal meningitis.隐球菌性脑膜炎患者脑脊液菌落形成单位计数与抗原滴度的基线相关性及比较动力学
J Infect Dis. 2005 Aug 15;192(4):681-4. doi: 10.1086/432073. Epub 2005 Jul 7.
4
Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.HIV 相关隐球菌性脑膜炎的联合抗真菌治疗：一项随机试验。
Lancet. 2004 May 29;363(9423):1764-7. doi: 10.1016/S0140-6736(04)16301-0.
5
Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis.两性霉素B和氟康唑，一种用于治疗隐球菌性脑膜炎的有效联合疗法。
Antimicrob Agents Chemother. 2004 Mar;48(3):985-91. doi: 10.1128/AAC.48.3.985-991.2004.
6
Antifungal susceptibility testing. New technology and clinical applications.抗真菌药敏试验。新技术与临床应用。
Infect Dis Clin North Am. 2001 Dec;15(4):1227-61. doi: 10.1016/s0891-5520(05)70192-6.
7
Early mycological treatment failure in AIDS-associated cryptococcal meningitis.艾滋病相关隐球菌性脑膜炎的早期真菌治疗失败
Clin Infect Dis. 1999 Jan;28(1):82-92. doi: 10.1086/515074.
8
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.获得性免疫缺陷综合征相关隐球菌性脑膜炎的治疗。美国国立过敏和传染病研究所真菌病研究组及艾滋病临床试验组。
N Engl J Med. 1997 Jul 3;337(1):15-21. doi: 10.1056/NEJM199707033370103.
9
Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.抗真菌药敏试验解释性断点的制定：氟康唑、伊曲康唑和念珠菌感染的体外-体内相关性数据的概念框架与分析。美国国家临床实验室标准委员会抗真菌药敏试验小组委员会
Clin Infect Dis. 1997 Feb;24(2):235-47. doi: 10.1093/clinids/24.2.235.
Zotero 插件